The present study extends our unique HSCT-based macrophage-mediated GDNF gene therapy strategy to a more clinically relevant animal model of PD, the MitoPark mouse, with adult onset and progressive disease manifestations. The gene discussed is GDNF; the disease is Parkinson disease.